Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability-Reference-Cited by-同舟云学术

Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability

Published:2017-03-04 Issue:3 Volume:44 Page:277-290
ISSN:1567-567X
Container-title:Journal of Pharmacokinetics and Pharmacodynamics
language:en
Short-container-title:J Pharmacokinet Pharmacodyn

Author:

Malik Paul R. V.,Hamadeh Abdullah,Phipps Colin,Edginton Andrea N.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/article/10.1007/s10928-017-9515-3/fulltext.html

Reference62 articles.

1. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2 + metastatic breast cancer. Cancer Chemother Pharmacol 56(4):361–369. doi: 10.1007/s00280-005-1026-z

2. Schmidt H (2013) SBPOP Package: efficient support for model based drug development—from mechanistic models to complex trial simulation. PAGE meeting, Glasgow

3. Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W (2007) Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn 34(3):401–431. doi: 10.1007/s10928-007-9053-5

4. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39(1):67–86. doi: 10.1007/s10928-011-9232-2

5. Cao Y, Jusko WJ (2014) Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn 41(4):375–387. doi: 10.1007/s10928-014-9372-2

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients;Cancer Chemotherapy and Pharmacology;2024-08-23

2. Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults – an AGePOP review;European Journal of Pharmaceutical Sciences;2023-09

3. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies;British Journal of Clinical Pharmacology;2023-05

4. Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities;Xenobiotica;2022-08-03

5. A Physiologically Based Pharmacokinetic Framework for Quantifying Antibody Distribution Gradients from Tumors to Tumor-Draining Lymph Nodes;Antibodies;2022-04-14